Truist Breaks Down The 'uptake and total addressable market of VRTX's NAV 1.8 pain drug VX-548'
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $508.00 price target on Vertex (NASDAQ: VRTX).The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
